These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 32275933)

  • 21. Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.
    Yeung KT; More S; Woodward B; Velculescu V; Husain H
    Mol Diagn Ther; 2017 Aug; 21(4):375-384. PubMed ID: 28337711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
    Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
    Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Cytomorphology in the Era of Liquid Biopsy.
    Clery E; Pisapia P; Vigliar E; Malapelle U; Bellevicine C; Troncone G; Schmitt FC
    Acta Cytol; 2019; 63(6):497-505. PubMed ID: 30943469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
    Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
    Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y; Wang H; He C
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
    Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
    Cancer Med; 2020 Jan; 9(1):12-18. PubMed ID: 31692291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Uchida J; Imamura F; Kukita Y; Oba S; Kumagai T; Nishino K; Inoue T; Kimura M; Kato K
    Cancer Sci; 2016 Mar; 107(3):353-8. PubMed ID: 26678713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.
    Tchekmedyian N; Mudad R; Blanco FF; Raymond VM; Garst J; Erlander MG; Haura E; Berz D
    Lung Cancer; 2017 Jun; 108():22-28. PubMed ID: 28625639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.
    Lee Y; Park S; Kim WS; Lee JC; Jang SJ; Choi J; Choi CM
    Thorac Cancer; 2018 Sep; 9(9):1104-1110. PubMed ID: 29989342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
    Krug AK; Enderle D; Karlovich C; Priewasser T; Bentink S; Spiel A; Brinkmann K; Emenegger J; Grimm DG; Castellanos-Rizaldos E; Goldman JW; Sequist LV; Soria JC; Camidge DR; Gadgeel SM; Wakelee HA; Raponi M; Noerholm M; Skog J
    Ann Oncol; 2018 Mar; 29(3):700-706. PubMed ID: 29216356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
    Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating tumor DNA testing in advanced non-small cell lung cancer.
    Moding EJ; Diehn M; Wakelee HA
    Lung Cancer; 2018 May; 119():42-47. PubMed ID: 29656751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
    Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.
    He J; Tan W; Tang X; Ma J
    Pathol Oncol Res; 2017 Apr; 23(2):307-315. PubMed ID: 27511219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of
    Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
    J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.